Garuda Construction and Engineering Limited is set to launch its IPO

Key Takeaways from Garuda Construction and Engineering Limited IPO:

• The Garuda Construction and Engineering Limited IPO comprises a fresh issue of up to 1,83,00,000 equity shares, along with an Offer for Sale of up to 95,00,000 shares by promoter PKH Ventures Limited. 
• The IPO will have a bidding period starting with anchor investors on October 7, 2024, followed by the opening of the IPO on October 8 and closing on October 10, 2024. This timeline provides investors with a structured approach to participation.
• The IPO has a clear allocation strategy, reserving not more than 50% for QIBs, at least 15% for NIIs, and a minimum of 35% for RIBs, ensuring a balanced participation from various investor categories.

In addition to the fresh issue, there will be an Offer for Sale of up to 95,00,000 equity shares by the promoter, PKH Ventures Limited. This brings the total offer size to a substantial 2,78,00,000 equity shares, allowing investors a significant opportunity to participate in the company's growth.

While the price band for the IPO is yet to be announced, it is anticipated that this information will be made available closer to the offer date. The minimum lot size for the bidding has not been disclosed yet but will be revealed as the IPO approaches. The tentative timeline for the IPO is as follows: the anchor investor bidding date is scheduled for October 7, 2024, with the main IPO opening on October 8, 2024, and closing on October 10, 2024. This timeline provides investors with ample time to evaluate their participation in the offering.

In terms of allocation, the IPO is designed to cater to various categories of investors. Qualified Institutional Buyers (QIBs) will be allocated not more than 50% of the total offer, while Non-Institutional Investors (NIIs) will receive a minimum of 15%. Retail Individual Bidders (RIBs) are assured a minimum allocation of 35% of the offer. This structured approach ensures a balanced and fair distribution among different investor segments, making Garuda Construction and Engineering Limited's IPO an appealing investment opportunity for a diverse range of market participants.

About Garuda Construction and Engineering Limited, 

Garuda Construction and Engineering Limited, established in 2010, is a construction company that offers a wide range of building services. They work on residential, commercial, industrial, and infrastructure projects, and also provide additional services for hospitality projects. In addition to construction, the company offers operation and maintenance (O&M), mechanical, electrical, and plumbing (MEP) services, along with finishing touches for various projects.

Key Takeaways from Paramount Dye Tec Limited IPO:

• The IPO is offering a fresh issue of up to 24,30,000 equity shares with a price band of ₹111 to ₹117 per share.
• Investors must bid for a minimum of 1,200 equity shares, with bids in multiples of 1,200 thereafter.
• The IPO is open from September 30, 2024, to October 3, 2024. Anchor investor bidding started on September 27, 2024.
• Shares will be listed on the NSE Emerge platform, with Gretex Share Broking Limited as the market maker.

The price band for the IPO is set between ₹111 and ₹117 per share. Interested investors can place a minimum bid for 1,200 equity shares. The IPO opened on September 30, 2024, and will close on October 3, 2024, while the anchor investor period began on September 27, 2024. The shares will be listed on the NSE Emerge platform, with Gretex Share Broking Limited acting as the market maker for the issue.

The allotment process for the IPO will follow this schedule: the finalisation of the basis of allotment is expected on or about October 4, 2024, with the initiation of refunds or unblocking of funds on October 7, 2024. The credit of shares to the respective Demat accounts is also slated for October 7, and the trading of the shares is set to commence on October 8, 2024. Investors are required to bid in multiples of 1,200 shares after the minimum bid.

The IPO reservation is distributed as follows: Qualified Institutional Buyers (QIBs) will receive up to 50% of the net issue, NonInstitutional Investors (NIIs) will be allocated at least 15%, and Retail Individual Bidders will get at least 35%. A total of 1,22,400 equity shares are reserved for the market maker. This structure ensures a balanced allocation across various investor categories, making the IPO an attractive opportunity for a wide range of market participants.

About Paramount Dye Tec Limited

Paramount Dye Tec Limited, founded in January 2014, specialises in producing high-quality yarns by recycling waste synthetic fibre. Catering to the B2B textile industry, the company offers a wide range of products, including acrylic, polyester, nylon, wool, and blend yarns. With two manufacturing facilities in Punjab, Paramount Dye Tec is ISO 9001:2015 and GMP certified, ensuring a strong focus on quality and durability in its offerings.

The partnership is one of the largest in the Indian diagnostics sector and focuses on improving patient care and accessibility. Krsnaa Diagnostics is recognised for its reach and reputation in providing affordable healthcare services. This partnership will leverage United Imaging’s advanced MRI, CT, and PET CT technologies to enhance diagnostic capabilities in underserved areas.

“We are thrilled to join hands with Medikabazaar and United imaging in what we see as a transformative alliance for the Indian diagnostics industry,” said Rajendra Mutha, Chairman of Krsnaa Diagnostics. “This collaboration not only enables us to expand our footprint into under-served regions but also strengthens our ability to offer cutting-edge imaging services at competitive prices. The unparalleled financial terms provided by United Imaging structured by Medikabazaar speak volumes about the trust they place in our operational excellence and leadership in the sector.” 

The initiative aims to transform diagnostic delivery in semi-urban and rural regions, making world-class imaging technologies available through Krsnaa's extensive network. This collaboration seeks to ensure that even remote populations have access to timely and accurate diagnostic testing, bridging the gap in quality healthcare services.

About Krsnaa Diagnostics Limited:

Krsnaa Diagnostics is a leading diagnostics service provider in India, with a network that spans 18 states and union territories. The company operates over 168 MRI and CT centers, more than 1,400 tele reporting X-ray centers, 120 labs, and over 2,200 collection centers. Krsnaa is dedicated to offering high-quality and affordable diagnostic services, utilizing an advanced cloud-based system that allows for quick deployment and easy integration into various healthcare settings.

About United Imaging and Medikabazaar:

United Imaging is a global leader in high-performance imaging equipment, focused on innovation in diagnostic technology. Medikabazaar is the largest B2B healthcare procurement and supply chain solutions provider in India. It offers a tech-enabled supply chain system that allows hospitals to easily procure the supplies and services they need, helping improve efficiency and making healthcare more affordable and accessible for patients across the country.

Key Takeaways from Sun Pharma Commercialisation of FIBROMUN:

• Sun Pharmaceutical Industries and Philogen S.p.A have entered into a global licensing agreement for Philogen’s specialty product, FIBROMUN (L19TNF).
• FIBROMUN is an innovative anti-cancer immunotherapy being studied for the treatment of soft tissue sarcoma and glioblastoma.
• Philogen will conduct ongoing clinical trials, seek regulatory approval, and manufacture the product, while Sun Pharma will manage all commercialisation efforts.
• The two companies will share the financial benefits in a 55:45 ratio, with Sun Pharma receiving the larger share.

Under this agreement, Sun Pharma will have exclusive rights to market FIBROMUN worldwide. Philogen will continue its pivotal clinical trials, seek marketing authorisation from regulatory bodies, and produce the product. Sun Pharma will handle all commercialisation efforts, and both companies will share the financial benefits in a 55:45 ratio, favouring Sun Pharma.

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, “Fibromun’s progress through development has been quite encouraging and it has potential to be an important option for treatment of soft-tissue sarcomas and other cancers with significant unmet medical needs.”

This agreement builds on their previous partnership for another product, Nidlegy™, which is also being developed for cancer treatment.

About Sun Pharmaceutical Industries Limited:

Sun Pharma is a leading global company in specialty generics, offering a wide range of products in specialty, generics, and consumer healthcare. It is the largest pharmaceutical company in India and a top generic drug provider in the US and other emerging markets. Sun Pharma's specialty portfolio includes innovative products in dermatology and oncology, which make up over 18% of its sales. The company operates manufacturing facilities across six continents and provides high-quality medicines trusted by healthcare professionals and consumers in over 100 countries. Sun Pharma prides itself on its diverse workforce, with employees from more than 50 nations.

About Philogen Group:

Philogen is a biotechnology company based in Italy and Switzerland, focused on creating new drugs for serious diseases. The company's mission is to find, develop, and sell innovative medicines for conditions with significant unmet medical needs. Philogen uses unique technologies to identify specific substances that target disease-related proteins, along with expertise in drug development and manufacturing. While many of its products are aimed at treating cancer, the company’s targeting methods could also be used for other diseases, including certain chronic inflammatory conditions.

About Fibromun:

Fibromun is a biopharmaceutical product developed by Philogen for treating advanced soft tissue sarcoma and glioblastoma. It combines the L19 antibody with Tumour Necrosis Factor (TNF). The L19 antibody specifically targets a protein called Fibronectin, which is found in tumours but not in most healthy tissues. TNF is a substance that can kill cancer cells, and the L19 antibody helps deliver it directly to tumours. Fibromun is given through an intravenous infusion and is currently in late-stage clinical trials for its potential use in treating these cancers. It may also be effective against other types of cancer, such as lung, breast, colon, and prostate cancers.